Related Experiment Video

Updated: Feb 19, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.8K

Historical epidemiology of hepatitis C virus in select countries-volume 4

A Maaroufi1, A Vince2, S M Himatt3

  • 1National Institute of Health Administration, Rabat, Morocco.

Journal of Viral Hepatitis
|November 7, 2017
PubMed

Insights

New hepatitis C virus (HCV) treatments require updated national control strategies. This study highlights data gaps in HCV prevalence and treatment across 17 countries, crucial for effective public health planning.

Area of Science:

  • Hepatology
  • Public Health
  • Epidemiology

Background:

  • The advent of novel, effective hepatitis C virus (HCV) treatments necessitates the evolution of national public health policies.
  • Understanding the current epidemiological landscape of chronic HCV infection is vital for adapting control strategies.

Purpose of the Study:

  • To characterize the burden of chronic HCV infection across 17 countries.
  • To identify data gaps in HCV prevalence, diagnosis, and treatment rates to inform policy development.

Main Methods:

  • A comprehensive literature review of published and unpublished data on HCV epidemiology was conducted.
  • Data on HCV prevalence, viraemia, genotype, demographics, liver transplants, and treatment rates were collected.
  • Expert consensus in each country was used to validate the gathered data.

Main Results:

  • Viraemic HCV prevalence varied significantly, from 0.2% in Hong Kong to 2.4% in Taiwan.
  • Nigeria and Taiwan reported the largest viraemic populations, with 2,597,000 and 569,000 cases, respectively.
  • Rates of diagnosis, treatment, and liver transplantation, along with data reliability, showed considerable cross-country variation.

Conclusions:

  • Significant disparities in HCV burden and management exist across countries.
  • Addressing data gaps is essential for developing targeted and effective national HCV control strategies.
  • Adapting public health policies to the changing epidemiology of hepatitis C is critical for disease management.

Keywords:
HCVdiagnosisdisease burdenepidemiologyhepatitis Chistoricalincidencemortalityprevalencetreatment

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.3K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
213
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
259
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Introduction to Epidemiology01:26

Introduction to Epidemiology

Epidemiology, known as the cornerstone of public health, involves studying the distribution and determinants of health-related events in defined populations and applying these insights to control health issues. This is essential for understanding how diseases spread, identifying populations at greater risk, and implementing measures to control or prevent outbreaks. Epidemiology addresses not only infectious diseases but also non-communicable conditions like cancer and cardiovascular disease,...
2.0K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
643
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
291